恩度联合奈达铂胸腔内灌注治疗恶性胸腔积液疗效观察  

Efficacy of Intrapleural Infusion of Endostar Combined with Nedaplatin in the Treatment of Malignant Pleural Effusion

作　　者：姚勤红[1] 林青凤[1] 刘少平[1] 沈冬[1] 林峰[1] 茅卫东[1] 

机构地区：[1]东南大学附属江阴市人民医院肿瘤科,江苏江阴214400

出　　处：《肿瘤基础与临床》2012年第6期492-494,共3页journal of basic and clinical oncology

摘　　要：目的探讨恩度联合奈达铂胸腔内灌注治疗恶性胸腔积液的有效性和安全性。方法将60例恶性胸腔积液患者随机分为试验组和对照组,2组患者均先采用胸腔穿刺置管闭式引流胸腔积液,试验组30例采用恩度(45 mg)联合奈达铂(40 mg)进行胸腔内灌注,而对照组30例仅采用奈达铂(40 mg)进行胸腔内灌注,观察2组的疗效和毒副反应。结果试验组有效率为76.67%,优于对照组的36.67%,差异有统计学意义(P<0.05);2组主要毒副反应发生率比较差异无统计学意义(P均>0.05);试验组生活质量改善率为73.33%,高于对照组的43.33%,差异有统计学意义(P<0.05)。结论恩度联合奈达铂胸腔内灌注治疗恶性胸腔积液安全有效。Objective To investigate the efficacy and safety of intrapleural infusion of endostar combined with nedaplatin in the treatment of malignant pleural effusion. Methods Sixty patients with malignant pleural effusion were randomly divided into two groups （ 30 patients of the test group and 30 patients of the control group）. The pleural effusion of all the patients in the two groups were discharged with pleural puncture catheter closed drainage ,30 patients of the test group received intrapleural infusion of endostar （45 mg） combined with nedaplatin （40 mg） , and 30 patients of the control group only received intrapleural infusion of nedaplatin （40 mg）. The efficacy and toxicities of the two groups was observed respectively. Results The response rate of the test group was 76.67%, and was 36.67 % of the control group （ P 〈 0.05 ）. There was no significant difference in the toxicities between the two groups （ P 〉 0.05 ）. The improvement rate of quality of life of the test group was 73.33 % , and was 43.33% of the control group （ P 〈 0.05 ）. Conclusion Intrapleural infusion of endostar com- bined with nedaplatin is effective and safe in the treatment of malignant pleural effusion.

关 键 词：恩度 奈达铂 恶性胸腔积液 胸腔内灌注 

分 类 号：R730.6[医药卫生—肿瘤] R730.58[医药卫生—临床医学]